BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+0.5%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.7B
AUM Growth
+$9.7B
(-1.5%)
Cap. Flow
+$400M
Cap. Flow
% of AUM
4.13%
Top 10 Holdings %
Top 10 Hldgs %
29.73%
Holding
233
New
14
Increased
61
Reduced
63
Closed
42
Top Buys
| 1 |
CareDx
CDNA
|
$65.3M |
| 2 |
Abbott
ABT
|
$50.4M |
| 3 |
Molina Healthcare
MOH
|
$46.5M |
| 4 |
Danaher
DHR
|
$44.5M |
| 5 |
Medtronic
MDT
|
$34M |
Top Sells
| 1 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$63.1M |
| 2 |
Centene
CNC
|
$40.7M |
| 3 |
Baxter International
BAX
|
$40.6M |
| 4 |
Hologic
HOLX
|
$22.3M |
| 5 |
DexCom
DXCM
|
$15.4M |
Sector Composition
| 1 | Healthcare | 97.85% |
| 2 | Technology | 0.8% |
| 3 | Industrials | 0.75% |
| 4 | Communication Services | 0.02% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Masimo
MASI
$7.43B
| $38.5M | 0.4% |
131,376
+3,663
| +3% | +$1.07M |
|
77
HUTCHMED
HCM
$2.62B
| $37.8M | 0.39% |
1,076,870
+70,723
| +7% | +$2.48M |
|
78
Cooper Companies
COO
$13.3B
| $34.9M | 0.36% |
333,276
+36,212
| +12% | +$3.79M |
|
79
AtriCure
ATRC
$1.73B
| $34.7M | 0.36% |
498,556
+80,540
| +19% | +$5.6M |
|
80
10x Genomics
TXG
$1.66B
| $34.7M | 0.36% |
232,672
| – | – |
|
81
Zimmer Biomet
ZBH
$20.8B
| $34.5M | 0.36% |
279,326
-9,158
| -3% | -$1.13M |
|
82
Teladoc Health
TDOC
$1.37B
| $33.4M | 0.34% |
363,216
+147,310
| +68% | +$13.5M |
|
83
Teleflex
TFX
$5.57B
| $32.1M | 0.33% |
97,771
-47
| -0% | -$15.4K |
|
84
Pacific Biosciences
PACB
$378M
| $31.8M | 0.33% |
1,553,023
-90,136
| -5% | -$1.84M |
|
85
Apellis Pharmaceuticals
APLS
$3.51B
| $30.8M | 0.32% |
650,591
+602,591
| +1,255% | +$28.5M |
|
86
Legend Biotech
LEGN
$6.64B
| $30.7M | 0.32% |
657,656
+371,100
| +130% | +$17.3M |
|
87
Bio-Rad Laboratories Class A
BIO
$7.8B
| $30M | 0.31% |
39,683
-6,332
| -14% | -$4.78M |
|
88
Guardant Health
GH
$8.11B
| $29.4M | 0.3% |
293,612
-46,282
| -14% | -$4.63M |
|
89
BioNTech
BNTX
$24.1B
| $29.3M | 0.3% |
113,466
+100,766
| +793% | +$26M |
|
90
Illumina
ILMN
$15.2B
| $28.6M | 0.29% |
77,234
+5,140
| +7% | +$1.9M |
|
91
Health Catalyst
HCAT
$228M
| $27.4M | 0.28% |
692,666
-34,567
| -5% | -$1.37M |
|
92
Generation Bio
GBIO
$40.3M
| $27.4M | 0.28% |
387,218
+140,000
| +57% | +$9.91M |
|
93
Mersana Therapeutics
MRSN
$34.8M
| $25.9M | 0.27% |
166,560
-3,880
| -2% | -$603K |
|
94
Outset Medical
OM
$245M
| $25.8M | 0.27% |
37,374
+6,903
| +23% | +$4.77M |
|
95
Charles River Laboratories
CRL
$7.99B
| $24.8M | 0.26% |
65,911
+2,582
| +4% | +$973K |
|
96
Phreesia
PHR
$1.81B
| $24.7M | 0.25% |
592,327
-30,215
| -5% | -$1.26M |
|
97
Axsome Therapeutics
AXSM
$6.09B
| $24.6M | 0.25% |
651,937
-101,008
| -13% | -$3.82M |
|
98
CVS Health
CVS
$93B
| $23.6M | 0.24% |
228,798
+70,250
| +44% | +$7.25M |
|
99
Esperion Therapeutics
ESPR
$490M
| $22.6M | 0.23% |
4,519,164
| – | – |
|
100
ResMed
RMD
$39.4B
| $22.5M | 0.23% |
86,490
-1,655
| -2% | -$431K |
|